Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis
Abstract Background Rituximab (RTX) has been previously reported as directed treatment in patients with connective-tissue disease-related interstitial lung diseases (CTD-ILD). A systematic assessment of treatment effect size on pulmonary function outcomes and related adverse effects in patients with...
Main Authors: | Yuanchen Zhao, Yang Gao, Tananchai Petnak, Wisit Cheungpasitporn, Charat Thongprayoon, Xing Zhang, Teng Moua |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-022-02082-x |
Similar Items
-
Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis
by: Linrui Xu, et al.
Published: (2022-10-01) -
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
by: Caterina Vacchi, et al.
Published: (2021-01-01) -
Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
by: Natalia Mena-Vázquez, et al.
Published: (2022-02-01) -
Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis
by: Pahnwat Taweesedt, et al.
Published: (2023-01-01) -
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
by: Panupong Hansrivijit, et al.
Published: (2020-04-01)